Replies to post #245699 on Biotech Values

[dewophile]

There were 2 severe cases requiring hospitalization and 2 cases of GBS in the trial. Some maybe figured where’s the risk benefit?
The flip side is you spared many from non-hospitalized RSV infection so benefits > harm (and potentially underestimates this as the study was in a fairly healthy population overall)
Anyway I think it was the right decision net net amd bodes well for GSK tomorrow